

# Kathleen I Pritchard, Cm

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7544095/publications.pdf>

Version: 2024-02-01

221  
papers

40,505  
citations

6840

81  
h-index

2823

197  
g-index

225  
all docs

225  
docs citations

225  
times ranked

33454  
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). <i>European Journal of Cancer</i> , 2021, 148, 287-296.	1.3	11
2	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13â€™864 women in seven randomised trials. <i>Lancet Oncology</i> , The, 2021, 22, 1139-1150.	5.1	147
3	The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. <i>Breast</i> , 2021, 60, 295-301.	0.9	2
4	Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 217-227.	1.1	16
5	Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening?. <i>Clinical Breast Cancer</i> , 2020, 20, e54-e64.	1.1	41
6	Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. <i>Npj Breast Cancer</i> , 2020, 6, 22.	2.3	7
7	The association between endocrine therapy use and dementia among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1132-1137.	0.5	7
8	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1386.	1.8	33
9	The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 6.	2.3	26
10	Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. <i>Journal of Clinical Oncology</i> , 2020, 38, 1875-1886.	0.8	59
11	Breast Cancer Screening: Beyond Mortality. <i>Journal of Breast Imaging</i> , 2019, 1, 161-165.	0.5	7
12	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2395-2405.	13.9	349
13	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â€™298 women with early breast cancer in 26 randomised trials. <i>Lancet</i> , The, 2019, 393, 1440-1452.	6.3	260
14	Identifying research priorities in the treatment of patients with early breast cancer: from the patient perspective. <i>Breast</i> , 2019, 48, S21-S22.	0.9	0
15	<i>A priori</i> prediction of breast tumour response to chemotherapy using quantitative ultrasound imaging and artificial neural networks. <i>Oncotarget</i> , 2019, 10, 3910-3923.	0.8	16
16	Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada. <i>Oncologist</i> , 2018, 23, 768-775.	1.9	19
17	Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2018, 91, 38-46.	1.3	17
18	An update on treatment for post-menopausal metastatic breast cancer in elderly patients. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 597-609.	0.9	1

#	ARTICLE	IF	CITATIONS
19	Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. <i>Clinical Breast Cancer</i> , 2018, 18, 78-87.	1.1	13
20	Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. <i>Journal of Clinical Oncology</i> , 2018, 36, 563-571.	0.8	19
21	Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases. <i>Scientific Reports</i> , 2018, 8, 9013.	1.6	27
22	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 111-121.	13.9	1,558
23	Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1041-1048.	0.8	87
24	A priori Prediction of Neoadjuvant Chemotherapy Response and Survival in Breast Cancer Patients using Quantitative Ultrasound. <i>Scientific Reports</i> , 2017, 7, 45733.	1.6	49
25	Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27. <i>Cancer</i> , 2017, 123, 2444-2451.	2.0	11
26	Plasma vascular endothelial growth factor as a predictive biomarker: Door closed?. <i>European Journal of Cancer</i> , 2017, 70, 143-145.	1.3	7
27	Extended adjuvant therapy: the role of subset analyses. <i>Lancet Oncology</i> , The, 2017, 18, 1431-1433.	5.1	0
28	Chemotherapy-Response Monitoring of Breast Cancer Patients Using Quantitative Ultrasound-Based Intra-Tumour Heterogeneities. <i>Scientific Reports</i> , 2017, 7, 10352.	1.6	44
29	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. <i>New England Journal of Medicine</i> , 2017, 377, 1836-1846.	13.9	1,052
30	Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer. <i>Oncologist</i> , 2017, 22, 12-24.	1.9	14
31	Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 1641-1649.	0.8	555
32	Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. <i>Cancer Research</i> , 2016, 76, 7012-7023.	0.4	47
33	P2-334: Cognitive Sequelae of Adjuvant Endocrine therapy for the Treatment of Breast Cancer in Older Women: A Feasibility Study. <i>Alzheimer's and Dementia</i> , 2016, 12, P770.	0.4	0
34	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw037.	3.0	24
35	Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 101-108.	1.1	0
36	An update on adjuvant systemic therapy for elderly patients with early breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1881-1888.	0.9	3

#	ARTICLE	IF	CITATIONS
37	Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 407-420.	1.1	47
38	Do aromatase inhibitors increase cardiovascular risk? Piecing together the evidence. <i>European Journal of Cancer</i> , 2016, 68, 176-178.	1.3	2
39	The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous?. <i>European Journal of Cancer</i> , 2016, 68, 173-175.	1.3	1
40	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. <i>New England Journal of Medicine</i> , 2016, 375, 209-219.	13.9	507
41	Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. <i>Breast Cancer Research</i> , 2016, 18, 1.	2.2	110
42	Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. <i>European Journal of Cancer</i> , 2016, 56, 85-92.	1.3	4
43	Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. <i>Journal of Clinical Oncology</i> , 2016, 34, 1065-1071.	0.8	65
44	The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 1097-1105.	1.0	81
45	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 419-426.	0.8	203
46	Quantitative ultrasound assessment of breast tumor response to chemotherapy using a multi-parameter approach. <i>Oncotarget</i> , 2016, 7, 45094-45111.	0.8	38
47	A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22. <i>SpringerPlus</i> , 2015, 4, 631.	1.2	8
48	Effect of Metformin vs Placebo on and Metabolic Factors in NCIC CTG MA.32. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv006-djv006.	3.0	112
49	Predicting Anthracycline Benefit: <i>TOP2A</i> and <i>CEP17</i> Not Only but Also. <i>Journal of Clinical Oncology</i> , 2015, 33, 1680-1687.	0.8	55
50	Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 265-271.	0.8	36
51	Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 439-448.	1.1	50
52	Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	0.6	1,449
53	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. <i>Oncologist</i> , 2015, 20, 474-482.	1.9	145
54	Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 605-611.	1.1	19

#	ARTICLE	IF	CITATIONS
55	Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 2005-2014.	13.9	1,146
56	Octreotide LAR and tamoxifen versus tamoxifen in phase III randomized early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 353-360.	1.1	4
57	Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. <i>Annals of Oncology</i> , 2014, 25, 992-998.	0.6	90
58	Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. <i>Annals of Oncology</i> , 2014, 25, 808-815.	0.6	112
59	Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 474-482.	5.1	45
60	Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. <i>Breast Cancer Research</i> , 2014, 16, R8.	2.2	31
61	The impact of a breast cancer diagnosis in young women on their relationship with their mothers. <i>Breast</i> , 2014, 23, 50-55.	0.9	15
62	Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women With Breast Cancer Receiving Letrozole: The LISA Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 2231-2239.	0.8	141
63	Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 153-162.	1.1	43
64	Competing risks of death in younger and older postmenopausal breast cancer patients. <i>World Journal of Clinical Oncology</i> , 2014, 5, 1088.	0.9	13
65	Population-based evaluation of 21-gene assay in treatment decision making for early breast cancer in Ontario.. <i>Journal of Clinical Oncology</i> , 2014, 32, 583-583.	0.8	3
66	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013, 24, 2206-2223.	0.6	2,805
67	Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2. <i>Clinical Breast Cancer</i> , 2013, 13, 421-432.e8.	1.1	104
68	Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2. <i>Journal of the National Cancer Institute</i> , 2013, 105, 654-663.	3.0	88
69	Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. <i>Advances in Therapy</i> , 2013, 30, 870-884.	1.3	430
70	Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. <i>Cancer</i> , 2013, 119, 1908-1915.	2.0	81
71	Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study. <i>European Journal of Cancer</i> , 2013, 49, 2621-2632.	1.3	53
72	Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 88-96.	5.1	128

#	ARTICLE	IF	CITATIONS
73	Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27â€”A Randomized Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1398-1404.	0.8	218
74	Health-related quality of life and disease symptoms in postmenopausal women with HR<sup>+</sup>, HER2<sup>âˆ’</sup> advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. <i>Current Medical Research and Opinion</i> , 2013, 29, 1463-1473.	0.9	24
75	Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 1033-1033.	0.8	3
76	Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013, 31, 553-553.	0.8	2
77	A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 555-555.	0.8	4
78	Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013, 31, 561-561.	0.8	5
79	Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney studyâ€”NCT00811369.. <i>Journal of Clinical Oncology</i> , 2013, 31, 574-574.	0.8	2
80	Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013, 31, 557-557.	0.8	0
81	The first 10 years experience with genetic testing (GT) for BRCA1/2 mutations in a publicly funded program at a tertiary care teaching hospital in Ontario, Canada.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1550-1550.	0.8	0
82	Clinical management and resolution of stomatitis in BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013, 31, 558-558.	0.8	4
83	Insulin- and Obesity-Related Variables in Early-Stage Breast Cancer: Correlations and Time Course of Prognostic Associations. <i>Journal of Clinical Oncology</i> , 2012, 30, 164-171.	0.8	180
84	Bone-Targeted Agents and Skeletal-Related Events in Breast Cancer Patients with Bone Metastases: The State of the Art. <i>Current Oncology</i> , 2012, 19, 259-268.	0.9	73
85	Prospective Study of 2-[ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography in the Assessment of Regional Nodal Spread of Disease in Patients With Breast Cancer: An Ontario Clinical Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 1274-1279.	0.8	83
86	Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial. <i>Clinical Cancer Research</i> , 2012, 18, 2402-2412.	3.2	132
87	Reply to P. Ameri et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 1396-1396.	0.8	0
88	Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100â€”000 women in 123 randomised trials. <i>Lancet</i> , The, 2012, 379, 432-444.	6.3	1,753
89	First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study. <i>Oncology</i> , 2012, 82, 218-227.	0.9	47
90	Everolimus in Postmenopausal Hormone-Receptorâ€”Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 520-529.	13.9	2,474

#	ARTICLE	IF	CITATIONS
91	Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.. Journal of Clinical Oncology, 2012, 30, 559-559.	0.8	15
92	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncology, The, 2011, 12, 236-244.	5.1	575
93	Estrogen receptor: is it predictive for response to cytotoxic as well as hormonal therapy?. Breast Cancer Research and Treatment, 2011, 127, 587-588.	1.1	1
94	Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Research and Treatment, 2011, 126, 215-220.	1.1	170
95	Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Research and Treatment, 2011, 126, 295-310.	1.1	83
96	Elevated Bone Turnover Predicts for Bone Metastasis in Postmenopausal Breast Cancer: Results of NCIC CTG MA.14. Journal of Clinical Oncology, 2011, 29, 3605-3610.	0.8	57
97	Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14. Journal of Clinical Oncology, 2011, 29, 3869-3876.	0.8	83
98	Long-Term Follow-Up of Women in Trials of Adjuvant Therapy for Breast Cancer: Is It Still Important?. Journal of Clinical Oncology, 2011, 29, 1651-1652.	0.8	10
99	Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients. Breast Cancer Research and Treatment, 2010, 119, 347-356.	1.1	18
100	High levels of uPA and PAI-1 predict a good response to anthracyclines. Breast Cancer Research and Treatment, 2010, 121, 625-626.	1.1	3
101	Multicenter, Randomized, Cross-Over Clinical Trial of Venlafaxine Versus Gabapentin for the Management of Hot Flashes in Breast Cancer Survivors. Journal of Clinical Oncology, 2010, 28, 5147-5152.	0.8	106
102	A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada's Clinical Trials Group Trial,) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50		
103	Obesity and Hormone Therapy in Breast Cancer: An Unfinished Puzzle. Journal of Clinical Oncology, 2010, 28, 3405-3407.	0.8	32
104	Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors. Journal of Clinical Oncology, 2010, 28, 4674-4682.	0.8	196
105	Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ: British Medical Journal, 2010, 340, c693-c693.	2.4	358
106	Phase I/II Trial of Metronomic Chemotherapy With Daily Dalteparin and Cyclophosphamide, Twice-Weekly Methotrexate, and Daily Prednisone As Therapy for Metastatic Breast Cancer Using Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor Levels As Markers of Response. Journal of Clinical Oncology, 2010, 28, 723-730.	0.8	82
107	Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer. Journal of Clinical Oncology, 2010, 28, 77-82.	0.8	131
108	Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Annals of Oncology, 2010, 21, 1246-1253.	0.6	20

#	ARTICLE	IF	CITATIONS
109	Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer. <i>Oncologist</i> , 2010, 15, 457-465.	1.9	104
110	Review of the Clinical Studies Using the 21-Gene Assay. <i>Oncologist</i> , 2010, 15, 447-456.	1.9	14
111	Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer. <i>Cancer Treatment Reviews</i> , 2010, 36, 54-62.	3.4	16
112	Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. <i>Lancet Oncology</i> , The, 2010, 11, 55-65.	5.1	1,252
113	American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. <i>Journal of Clinical Oncology</i> , 2009, 27, 3235-3258.	0.8	254
114	Commentary: Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era?. <i>Oncologist</i> , 2009, 14, 959-962.	1.9	4
115	Are HER2 and TOP2A Useful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2009, 27, 3875-3876.	0.8	20
116	Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3757-3763.	0.8	305
117	Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163. <i>Journal of Clinical Oncology</i> , 2009, 27, 4536-4541.	0.8	246
118	Adjuvant targeted therapy in early breast cancer. <i>Cancer</i> , 2009, 115, 1154-1168.	2.0	32
119	Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 387-389.	1.1	37
120	High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 517-525.	1.1	77
121	Tailored targeted therapy for all: a realistic and worthwhile objective against. <i>Breast Cancer Research</i> , 2009, 11, S8.	2.2	1
122	Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. <i>Lancet Oncology</i> , The, 2009, 10, 1077-1085.	5.1	29
123	Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. <i>Lancet</i> , The, 2009, 374, 2055-2063.	6.3	237
124	Endocrine Therapy with Selective Estrogen Receptor Modulators (SERMs) and Aromatase Inhibitors in the Prevention and Adjuvant Therapy Settings. <i>Cancer Treatment and Research</i> , 2009, 147, 1-29.	0.2	1
125	Guidelines, Consensus Conferences and Overviews (Meta-analysis). <i>Cancer Treatment and Research</i> , 2009, 151, 63-76.	0.2	0
126	HER2/neu in systemic therapy for women with breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 209-229.	1.1	81



#	ARTICLE	IF	CITATIONS
127	Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer. <i>Cancer</i> , 2008, 112, 260-267.	2.0	119
128	Combining endocrine agents with chemotherapy: Which patients and what sequence?. <i>Cancer</i> , 2008, 112, 718-722.	2.0	31
129	Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2008, 8, 501-505.	1.1	214
130	Who should participate in clinical trials and who not? Can clinical trials be made more efficient and effective?. <i>Breast Cancer Research</i> , 2008, 10, S23.	2.2	0
131	Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2008, 34, 157-174.	3.4	80
132	Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2008, 34, 539-557.	3.4	73
133	Endocrine symptoms to predict risk of recurrence?. <i>Lancet Oncology</i> , The, 2008, 9, 1117-1119.	5.1	8
134	Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17. <i>Journal of Clinical Oncology</i> , 2008, 26, 1956-1964.	0.8	130
135	HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 736-744.	0.8	162
136	Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16. <i>Journal of Clinical Oncology</i> , 2008, 26, 37-43.	0.8	53
137	Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen. <i>Journal of Clinical Oncology</i> , 2008, 26, 1948-1955.	0.8	176
138	Cancer Treatmentâ€“Induced Bone Loss in Breast and Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 5465-5476.	0.8	164
139	Identification of Cancer Care and Protocol Characteristics Associated With Recruitment in Breast Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 4458-4465.	0.8	37
140	Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. <i>Journal of Clinical Oncology</i> , 2007, 25, 2006-2011.	0.8	126
141	Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Nonâ€“Small-Cell Lung Cancer With Disease-Related Anemia. <i>Journal of Clinical Oncology</i> , 2007, 25, 1027-1032.	0.8	392
142	Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System. <i>Journal of Clinical Oncology</i> , 2007, 25, 2127-2132.	0.8	709
143	Risk of chemotherapy induced menopause: More detailed data will lead to improved quality of life. <i>European Journal of Cancer</i> , 2007, 43, 1644-1645.	1.3	2
144	Therapeutic options for the management of hot flashes in breast cancer survivors: An evidence-based review. <i>Clinical Therapeutics</i> , 2007, 29, 230-241.	1.1	94

#	ARTICLE	IF	CITATIONS
145	Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. <i>Clinical Cancer Research</i> , 2007, 13, 4429-4434.	3.2	3,807
146	Adjuvant therapy of the very young woman. <i>Breast</i> , 2007, 16, 136-146.	0.9	22
147	Adjuvant and extended adjuvant use of aromatase inhibitors: Reducing the risk of recurrence and distant metastasis. <i>Breast</i> , 2007, 16, 1-9.	0.9	11
148	Selective Application of Axillary Node Dissection in Elderly Women with Early Breast Cancer. <i>Annals of Surgical Oncology</i> , 2007, 14, 652-659.	0.7	16
149	Cardiovascular Health and Aromatase Inhibitors. <i>Drugs</i> , 2006, 66, 1727-1740.	4.9	23
150	Ascertaining Prognosis for Breast Cancer in Node-Negative Patients with Innovative Survival Analysis. <i>Breast Journal</i> , 2006, 12, 37-47.	0.4	16
151	Biological Significance of Occult Micrometastases in Histologically Negative Axillary Lymph Nodes in Breast Cancer Patients Using the Recent American Joint Committee on Cancer Breast Cancer Staging System. <i>Breast Journal</i> , 2006, 12, 294-301.	0.4	63
152	Body radiation exposure in breast cancer radiotherapy: Impact of breast IMRT and virtual wedge compensation techniques. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 52-58.	0.4	68
153	Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. <i>Breast Cancer Research and Treatment</i> , 2006, 99, 295-300.	1.1	89
154	HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. <i>New England Journal of Medicine</i> , 2006, 354, 2103-2111.	13.9	498
155	Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate Therapy. <i>Journal of Clinical Oncology</i> , 2006, 24, 4895-4900.	0.8	130
156	Randomized Trial of Long-Term Follow-Up for Early-Stage Breast Cancer: A Comparison of Family Physician Versus Specialist Care. <i>Journal of Clinical Oncology</i> , 2006, 24, 848-855.	0.8	483
157	Managing Patients on Endocrine Therapy: Focus on Quality-of-Life Issues. <i>Clinical Cancer Research</i> , 2006, 12, 1056s-1060s.	3.2	33
158	Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17. <i>Journal of Clinical Oncology</i> , 2006, 24, 3629-3635.	0.8	285
159	Adjuvant endocrine therapies for pre-/perimenopausal women. <i>Breast</i> , 2005, 14, 547-554.	0.9	5
160	Prognostic factors affecting the natural history of node-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 89, 35-45.	1.1	42
161	Serum Lipids and Outcome of Early-stage Breast Cancer: Results of a Prospective Cohort Study. <i>Breast Cancer Research and Treatment</i> , 2005, 94, 135-144.	1.1	62
162	Aromatase Inhibitors in Adjuvant Therapy of Breast Cancer: Before, Instead of, or Beyond Tamoxifen. <i>Journal of Clinical Oncology</i> , 2005, 23, 4850-4852.	0.8	21

#	ARTICLE	IF	CITATIONS
163	Incidence and Prognostic Impact of Amenorrhea During Adjuvant Therapy in High-Risk Premenopausal Breast Cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Studyâ€”NCIC CTG MA.5. <i>Journal of Clinical Oncology</i> , 2005, 23, 6002-6008.	0.8	129
164	Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. <i>Journal of Clinical Oncology</i> , 2005, 23, 5166-5170.	0.8	189
165	Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women. <i>Journal of Clinical Oncology</i> , 2005, 23, 6931-6940.	0.8	227
166	A review of exemestane in the management of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2353-2363.	0.9	2
167	Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1262-1271.	3.0	1,048
168	American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptorâ€”Positive Breast Cancer: Status Report 2004. <i>Journal of Clinical Oncology</i> , 2005, 23, 619-629.	0.8	810
169	Is Leptin a Mediator of Adverse Prognostic Effects of Obesity in Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2005, 23, 6037-6042.	0.8	76
170	Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women. <i>Breast Cancer Research</i> , 2005, 7, 70-6.	2.2	18
171	Phase III Study of N,N-Diethyl-2-[4-(Phenylmethyl) Phenoxy]Ethanamine (BMS-217380-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. <i>Journal of Clinical Oncology</i> , 2004, 22, 269-276.	0.8	59
172	Why Cancer Patients Enter Randomized Clinical Trials: Exploring the Factors That Influence Their Decision. <i>Journal of Clinical Oncology</i> , 2004, 22, 4312-4318.	0.8	128
173	Health-Related Quality of Life and Psychosocial Status in Breast Cancer Prognosis: Analysis of Multiple Variables. <i>Journal of Clinical Oncology</i> , 2004, 22, 4184-4192.	0.8	98
174	Is expert breast pathology assessment necessary for the management of ductal carcinoma in situ?. <i>Breast Cancer Research and Treatment</i> , 2004, 87, 265-272.	1.1	28
175	The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 86-96.	0.8	90
176	Is exercise effective in reducing the risk of breast cancer in postmenopausal women?. <i>Cmaj</i> , 2004, 170, 787-787.	0.9	2
177	A Comparison of Risk Perception and Psychological Morbidity in Women with Ductal Carcinoma in situ and Early Invasive Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 77, 285-293.	1.1	145
178	The best use of adjuvant endocrine treatments. <i>Breast</i> , 2003, 12, 497-508.	0.9	15
179	A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer. <i>New England Journal of Medicine</i> , 2003, 349, 1793-1802.	13.9	1,723
180	Helping Patients Make Informed Choices: A Randomized Trial of a Decision Aid for Adjuvant Chemotherapy in Lymph Node-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2003, 95, 581-587.	3.0	205

#	ARTICLE	IF	CITATIONS
181	Quality of Life in a Randomized Trial of Group Psychosocial Support in Metastatic Breast Cancer: Overall Effects of the Intervention and an Exploration of Missing Data. <i>Journal of Clinical Oncology</i> , 2003, 21, 1944-1951.	0.8	124
182	Diet and Breast Cancer: Evidence That Extremes in Diet Are Associated With Poor Survival. <i>Journal of Clinical Oncology</i> , 2003, 21, 2500-2507.	0.8	84
183	Risk of Acute Leukemia Following Epirubicin-Based Adjuvant Chemotherapy: A Report From the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 3066-3071.	0.8	90
184	American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting. <i>Journal of Clinical Oncology</i> , 2003, 21, 2597-2599.	0.8	81
185	Optimal Chemotherapy for Women With Breast Cancer: The Plot Thickens. <i>Journal of Clinical Oncology</i> , 2003, 21, 963-964.	0.8	8
186	neu/erbB-2 Overexpression and Response to Hormonal Therapy in Premenopausal Women in the Adjuvant Breast Cancer Setting: Will It Play in Peoria? Part II. <i>Journal of Clinical Oncology</i> , 2003, 21, 399-400.	0.8	12
187	American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor-Positive Breast Cancer: Status Report 2002. <i>Journal of Clinical Oncology</i> , 2002, 20, 3317-3327.	0.8	213
188	Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 42-51.	0.8	798
189	Adjuvant Therapy for Premenopausal Women With Breast Cancer: Is It Time for Another Paradigm Shift?. <i>Journal of Clinical Oncology</i> , 2002, 20, 4611-4614.	0.8	29
190	Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. <i>Breast Cancer Research and Treatment</i> , 2002, 74, 65-76.	1.1	98
191	Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer. <i>Cmaj</i> , 2002, 166, 1017-22.	0.9	8
192	The Effect of Group Psychosocial Support on Survival in Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2001, 345, 1719-1726.	13.9	819
193	Use of ErbB-1 and ErbB-2 to Select Endocrine Therapy for Breast Cancer: Will It Play in Peoria?. <i>Journal of Clinical Oncology</i> , 2001, 19, 3795-3797.	0.8	20
194	A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis. <i>Cancer</i> , 2001, 92, 23-29.	2.0	9
195	Hormone Replacement in Women with a History of Breast Cancer. <i>Oncologist</i> , 2001, 6, 353-362.	1.9	20
196	Current and future directions in medical therapy for breast carcinoma. <i>Cancer</i> , 2000, 88, 3065-3072.	2.0	24
197	Should Tamoxifen Be Used to Treat Premenopausal Women with Breast Cancer?. <i>Cancer Investigation</i> , 2000, 18, 685-686.	0.6	5
198	Adjuvant Treatment and Onset of Menopause Predict Weight Gain After Breast Cancer Diagnosis. <i>Journal of Clinical Oncology</i> , 1999, 17, 120-120.	0.8	278

#	ARTICLE	IF	CITATIONS
199	The fox guarding the clinical trial: internal vs. external validity in randomized studies. , 1999, 8, 275-275.		8
200	Risk of Menopause During the First Year After Breast Cancer Diagnosis. Journal of Clinical Oncology, 1999, 17, 2365-2365.	0.8	503
201	Multidisciplinary weight management in locoregional breast cancer: results of a phase II study. Breast Cancer Research and Treatment, 1998, 48, 53-64.	1.1	107
202	Is tamoxifen effective in prevention of breast cancer?. Lancet, The, 1998, 352, 80-81.	6.3	95
203	Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer. Nature Medicine, 1997, 3, 227-230.	15.2	770
204	A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1. Breast Cancer Research and Treatment, 1997, 44, 211-215.	1.1	55
205	An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Research and Treatment, 1997, 44, 201-210.	1.1	79
206	Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folic acid in patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology, 1997, 41, 53-60.	1.1	3
207	Attitudes of Canadian Oncology Practitioners Toward Psychosocial Interventions in Clinical and Research Settings in Women With Breast Cancer. , 1997, 6, 178-189.		24
208	Attitudes of Canadian Oncology Practitioners Toward Psychosocial Interventions in Clinical and Research Settings in Women With Breast Cancer. , 1997, 6, 178.		3
209	Randomized trial of group psychosocial support in metastatic breast cancer: the BEST study. Cancer Treatment Reviews, 1996, 22, 91-96.	3.4	40
210	Menopausal estrogen replacement therapy in women with breast cancer. Cancer, 1995, 75, 1-3.	2.0	27
211	The Henrietta Banting Breast Centre database: A model for clinical research utilizing a hospital-based inception cohort. Journal of Clinical Epidemiology, 1995, 48, 779-786.	2.4	13
212	Droloxifene, a new antiestrogen: Its role in metastatic breast cancer. Breast Cancer Research and Treatment, 1994, 31, 83-94.	1.1	77
213	A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. European Journal of Cancer, 1993, 29, 37-43.	1.3	19
214	The standardization of estrogen receptors. Journal of Steroid Biochemistry and Molecular Biology, 1993, 45, 367-373.	1.2	13
215	Ondansetron Compared with Dexamethasone and Metoclopramide as Antiemetics in the Chemotherapy of Breast Cancer with Cyclophosphamide, Methotrexate, and Fluorouracil. New England Journal of Medicine, 1993, 328, 1081-1084.	13.9	76
216	A comparison of all-subset Cox and accelerated failure time models with Cox step-wise regression for node-positive breast cancer. Breast Cancer Research and Treatment, 1992, 22, 263-272.	1.1	28

#	ARTICLE	IF	CITATIONS
217	The Use of Endocrine Therapy. Hematology/Oncology Clinics of North America, 1989, 3, 765-805.	0.9	27
218	Systemic Adjuvant Therapy for Node-Negative Breast Cancer: Proven or Premature?. Annals of Internal Medicine, 1989, 111, 1.	2.0	15
219	The efficacy of bone scanning in the follow-up of patients with operable breast cancer. Breast Cancer Research and Treatment, 1984, 4, 303-307.	1.1	54
220	Tamoxifen and Hypercalcemia. Annals of Internal Medicine, 1978, 89, 423.	2.0	6
221	Tamoxifen and Metastatic Breast Cancer. Annals of Internal Medicine, 1978, 89, 721.	2.0	5